AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had its price objective hoisted by stock analysts at Piper Jaffray Companies from $3.80 to $4.50 in a research report issued on Monday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price points to a potential upside of 17.19% from the stock’s current price.

Several other equities research analysts have also recently commented on the company. Zacks Investment Research upgraded AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research note on Monday, July 24th. FBR & Co restated a “buy” rating and issued a $3.00 target price on shares of AVEO Pharmaceuticals in a research note on Friday, June 30th. ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 24th. Finally, BidaskClub upgraded AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $3.42.

AVEO Pharmaceuticals (AVEO) traded up 1.05% during midday trading on Monday, reaching $3.84. 31,490,793 shares of the company were exchanged. AVEO Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $4.24. The firm’s 50-day moving average price is $2.82 and its 200 day moving average price is $1.34. The stock’s market capitalization is $454.30 million.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/28/aveo-pharmaceuticals-inc-aveo-price-target-raised-to-4-50-at-piper-jaffray-companies.html.

A number of large investors have recently added to or reduced their stakes in AVEO. RA Capital Management LLC purchased a new stake in AVEO Pharmaceuticals during the second quarter valued at approximately $18,727,000. NEA Management Company LLC boosted its stake in AVEO Pharmaceuticals by 57.9% in the first quarter. NEA Management Company LLC now owns 16,362,694 shares of the biopharmaceutical company’s stock valued at $9,654,000 after buying an additional 6,000,000 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in AVEO Pharmaceuticals during the first quarter valued at approximately $1,711,000. Perceptive Advisors LLC boosted its stake in AVEO Pharmaceuticals by 64.3% in the first quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock valued at $3,014,000 after buying an additional 2,000,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in AVEO Pharmaceuticals by 48.6% in the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the last quarter. Hedge funds and other institutional investors own 53.76% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

The Fly

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.